Penumbra IPO Preliminary Points

Whirly lollipop on orange background.

We were impressed by the Penumbra (NYSE:PEN) neuro and vascular technologies demonstrated in their roadshow. Combined with their meaningful revenue ($125M in 2014 which was up 41%) and profitability this is an IPO to watch and probably own. Being able to effectively treat stroke victims is a big deal. Although they have a portfolio of products the ability to remove blood clots that cause a stroke is what really caught our attention.

It was in late 2014 that a definitive paper was published showing that intra-arterial treatment was far more effective at treating stroke than medicinal treatments . . .

Want the rest of the article?

Please login or join us as a member to view our complete content!